Cinclus Pharma Holding AB ((SE:CINPHA)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Cinclus Pharma Holding AB is conducting a Phase 3 clinical study titled ‘A Randomized, Phase 3, Double-blind, Double-dummy, Active Comparator-controlled Multicenter Study to Evaluate the Efficacy and Safety of 2 Doses of Linaprazan Glurate Compared to Lansoprazole in 4 or 8 Weeks Healing in Participants With Erosive Esophagitis (EE) Due to Gastroesophageal Reflux Disease (GERD) of Los Angeles (LA) Grades A to D.’ The study aims to assess the effectiveness and safety of linaprazan glurate in healing erosive esophagitis caused by GERD, compared to the widely used lansoprazole. This research is significant as it could offer a new treatment option for GERD patients.
The study tests two doses of linaprazan glurate (50 mg twice daily and 50 mg once daily) against lansoprazole (30 mg once daily). Linaprazan glurate is an experimental drug intended to heal erosive esophagitis and reduce heartburn symptoms more effectively than lansoprazole.
This interventional study is randomized and employs a parallel assignment model with quadruple masking, meaning participants, care providers, investigators, and outcomes assessors are unaware of the treatment allocations. The primary purpose is treatment-focused, aiming to establish the efficacy and safety of linaprazan glurate.
The study is set to begin in September 2025, with an estimated primary completion and overall completion date yet to be announced. The last update was submitted in June 2025, indicating preparations are underway for recruitment.
The potential success of linaprazan glurate could positively impact Cinclus Pharma’s stock performance by introducing a competitive alternative in the GERD treatment market. This development may also influence investor sentiment, as the pharmaceutical industry continuously seeks innovative solutions to common health issues.
The study is ongoing, and further details can be found on the ClinicalTrials portal.